Cargando…

A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression

Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to play a protective role against atherosclerosis in both animal models and patients with type 2 diabetes (T2D). However, since T2D is associated with dyslipidemia, hypertension and insulin resistance, part of which are ameliorated by DPP-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terasaki, Michishige, Yashima, Hironori, Mori, Yusaku, Saito, Tomomi, Matsui, Takanori, Hiromura, Munenori, Kushima, Hideki, Osaka, Naoya, Ohara, Makoto, Fukui, Tomoyasu, Hirano, Tsutomu, Yamagishi, Sho-ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369823/ https://www.ncbi.nlm.nih.gov/pubmed/32646003 http://dx.doi.org/10.3390/ijms21134811

Ejemplares similares

A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients
por: Terasaki, Michishige, et al.
Publicado: (2018)

Anti-inflammatory and atheroprotective properties of glucagon
por: Osaka, Naoya, et al.
Publicado: (2020)

Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-β2
por: Hiromura, Munenori, et al.
Publicado: (2022)

AGE-RAGE Axis Stimulates Oxidized LDL Uptake into Macrophages through Cyclin-Dependent Kinase 5-CD36 Pathway via Oxidative Stress Generation
por: Yashima, Hironori, et al.
Publicado: (2020)

Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
por: Terasaki, Michishige, et al.
Publicado: (2017)

Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
por: Osaka, Naoya, et al.
Publicado: (2022)

Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling
por: Mori, Yusaku, et al.
Publicado: (2019)

Very rare case of Graves’ disease with resistance to methimazole: a case report and literature review
por: Mori, Yusaku, et al.
Publicado: (2021)

Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes
por: Fujikawa, Tomoki, et al.
Publicado: (2021)

The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis
por: Kushima, Hideki, et al.
Publicado: (2017)

Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway
por: Terasaki, Michishige, et al.
Publicado: (2021)

Association of Hemoglobin A1c, 1,5-Anhydro-d-Glucitol and Glycated Albumin with Oxidative Stress in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study
por: Kohata, Yo, et al.
Publicado: (2020)

Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
por: Terasaki, Michishige, et al.
Publicado: (2015)

Comparison of positive rates between glutamic acid decarboxylase antibodies and ElisaRSR™ 3 Screen ICA™ in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes
por: Takehana, Nobuaki, et al.
Publicado: (2023)

Nesfatin-1 suppresses peripheral arterial remodeling without elevating blood pressure in mice
por: Mori, Yusaku, et al.
Publicado: (2019)

Pancreatic fat accumulation evaluated by multidetector computed tomography in patients with type 2 diabetes
por: Fukase, Ayako, et al.
Publicado: (2020)

Emphysematous cystitis in an elderly Japanese patient with type 2 diabetes mellitus
por: Yashima, Hironori, et al.
Publicado: (2019)

SMTP-44D Inhibits Atherosclerotic Plaque Formation in Apolipoprotein-E Null Mice Partly by Suppressing the AGEs-RAGE Axis †
por: Terasaki, Michishige, et al.
Publicado: (2023)

Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
por: Terasaki, Michishige, et al.
Publicado: (2013)

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
por: Hirano, Tsutomu, et al.
Publicado: (2023)

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes
por: Ito, Rika, et al.
Publicado: (2015)

Association of glucose and blood pressure variability on oxidative stress in patients with type 2 diabetes mellitus and hypertension: a cross-sectional study
por: Ohara, Makoto, et al.
Publicado: (2019)

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
por: Nagaike, Hiroe, et al.
Publicado: (2019)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Anti‐atherogenic and anti‐inflammatory properties of glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypepide, and dipeptidyl peptidase‐4 inhibitors in experimental animals
por: Hirano, Tsutomu, et al.
Publicado: (2016)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
por: Yamagishi, Sho-ichi, et al.
Publicado: (2015)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Identification of Dipeptidyl-Peptidase (DPP)5 and DPP7 in Porphyromonas endodontalis, Distinct from Those in Porphyromonas gingivalis
por: Nishimata, Haruka, et al.
Publicado: (2014)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Tackling dipeptidyl peptidase IV in neurological disorders
por: Al-Badri, Ghaith, et al.
Publicado: (2018)

Dipeptidyl Peptidase IV as a Muscle Myokine
por: Kluess, Heidi A.
Publicado: (2020)

Angioedema associated with dipeptidyl peptidase-IV inhibitors
por: Cassano, Nicoletta, et al.
Publicado: (2021)

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme)()
por: Juillerat-Jeanneret, Lucienne, et al.
Publicado: (1997)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells
por: Kitagawa, Noriyuki, et al.
Publicado: (2018)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
por: Hong, Sangmo, et al.
Publicado: (2022)

Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
por: Torrecillas-Baena, Bárbara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p7anurahfh7nkijigj3edccq6i